2seventy bio, Inc.
2seventy bio, Inc. (TSVT): 3 pipeline candidates · ~36 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
35.8 months
D/E 1.24 · 2% dilution
Lead: Approved
3 candidates
N/A
N/A
A transparent, data-derived signal for 2seventy bio, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$102.0M
Quarterly Burn
$11.0M
Runway
35.8 mo
Revenue
$22.9M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| abecma | Approved |
| bbt369 | Phase 2 |
| sc-daric33 | Phase 1 |
Frequently asked questions
How many drug candidates are in 2seventy bio, Inc.'s pipeline?
2seventy bio, Inc. (TSVT) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is 2seventy bio, Inc.'s lead drug candidate?
2seventy bio, Inc.'s most advanced tracked candidate is abecma (Approved) for Multiple myeloma.
What is 2seventy bio, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, 2seventy bio, Inc. has approximately 35.8 months of cash runway.
Who is the CEO of 2seventy bio, Inc.?
Chip Baird is the chief executive officer of 2seventy bio, Inc. (TSVT).
Get the full picture on 2seventy bio, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.